From the ACI website:
The rules of the pharmaceutical patent endgame are changing rapidly. Pharmaceutical patent expirations equaling $140 Billion in losses will occur within the next ten years. Congress, the PTO and the Courts are now reshaping the current pharmaceutical patent schematic. A new pharmaceutical patent paradigm is about to emerge.
Come to the only event that will enable brand name and generic drug makers to benchmark their companies' current Hatch-Waxman strategies against this new paradigm.
On Wednesday, October 24th at 3:15pm, Loeb & Loeb Partner Mark Waddell, along with M. Howard Morse of Drinker Biddle & Reath LLP, will discuss "Brand Name and Generic Pharmaceutical Patent Settlements: Pending Legislation, Key Cases and Strategies to Employ."
Discussion will include how the Hatch-Waxman reforms under title XI of the MMA mandated that pharmaceutical companies provide the FTC with advance notice of proposed settlements of patent disputes. The FTC and state attorneys general have challenged a number of settlements on antitrust grounds and settled several cases. Private litigation raising similar claims has followed. Although the Supreme Court denied certiorari in the FTC v. Schering case, questions still loom as to whether brand name and generic patent disputes can ever be settled without ensuing controversy. Pending legislation in both the House and the Senate only add to this uncertainty. This session will examine recent developments – in Congress and the courts — and discuss their implications for the future of settlement strategies.